Latest News & Features
Europe
A much-anticipated referral could upend the EPO’s controversial description amendment rule—and reshape European patent practice, as the Enlarged Board of Appeal prepares to weigh in on G 1/25. 5 August 2025
Europe
UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent. 4 August 2025
Unified Patent Court
Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN. 4 August 2025
Europe
German Federal Patent Court invalidates key patent for Xarelto | Bayer faces intensifying generic competition across Europe | Legal team highlights Germany’s crucial role in patent litigation and the importance of stopping early generic entry to protect market exclusivity. 1 August 2025
Americas
Settlement ends expectations of SCOTUS petition | Federal Circuit stipulates patents must explicitly claim the active ingredient of a drug to qualify for Orange Book listing | FTC backs Amneal, saying ‘improper listings’ stifle generic competition. 31 July 2025
Europe
The pharma manufacturer defeats an Italian hemp firm’s EU trademark bid | Claimed name could be confused for its blockbuster drug Xanax | EUIPO found strong market position and product overlap created risk of confusion. 31 July 2025
Careers
The team brings decades of litigation experience, with practices covering sectors from AI and life sciences to software and medical devices, as the firm prepares to open a new office in San Diego. 31 July 2025
Americas
This LSPN panel brings together experts from Troutman Pepper Locke, Sauvegarder Investment Management, Beam Therapeutics, Editas Med, and Takeda to explore the expanding role of IP lawyers in the life sciences industry. 31 July 2025
Americas
The outcome of Apple’s smartwatch dispute at the Federal Circuit may provide important guidance for meeting the US’ threshold domestic industry requirement, write Nathan Mammen and Cole Tipton of Snell & Wilmer. 30 July 2025
Americas
Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”. 29 July 2025